Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 88 EV-to-EBITDA is 3.81 as of Sep. 08, 2026, which is 69% below its 10-year median of 12.17. GuruFocus rates ROCO:8432 with a GF Score™ of 88/100 and a GF Value™ of NT$71.57 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 726 Drug Manufacturers companies, TSH Biopharm ranks better than 91.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, TSH Biopharm's enterprise value is NT$1,138 Mil.
TSH Biopharm's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$299 Mil. Therefore, TSH Biopharm's EV-to-EBITDA for today is 3.81.
The historical rank and industry rank for TSH Biopharm's EV-to-EBITDA or its related term are showing as below:
ROCO:8432'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -186.82 Med: 12.17 Max: 35.84
Current: 3.81
During the past 13 years, the highest EV-to-EBITDA of TSH Biopharm was 35.84. The lowest was -186.82. And the median was 12.17.
ROCO:8432's EV-to-EBITDA is ranked better than 91.46% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.75
vs ROCO:8432: 3.81
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TSH Biopharm's PE Ratio (TTM) for today is calculated as:
TSH Biopharm's share price for today is NT$50.30.
TSH Biopharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4.350.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for TSH Biopharm's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's EV-to-EBITDA falls into.
TSH Biopharm's current Enterprise Value is NT$1,138 Mil.
TSH Biopharm's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$299 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm (ROCO:8432) has a EV-to-EBITDA of 3.81 as of Sep. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TSH Biopharm. This is 69% below median its historical median of 12.17. According to the industry distribution chart, TSH Biopharm ranks #62 out of 726 companies in the Drug Manufacturers industry, placing it in the top 8.5%.
Is TSH Biopharm's EV-to-EBITDA too high?
TSH Biopharm's current EV-to-EBITDA of 3.81 is 69% below median its 10-year median of 12.17. The Drug Manufacturers industry median EV-to-EBITDA is 13.75. TSH Biopharm's value of 3.81 is 72.3% below this industry median. Based on the distribution chart, TSH Biopharm ranks #62 out of 726 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TSH Biopharm has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #62 out of 726 companies for EV-to-EBITDA. This places TSH Biopharm in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.75. TSH Biopharm's value of 3.81 is 72.3% below this benchmark. While the company's 10-year median is 12.17 vs. the industry median of 13.75, TSH Biopharm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.75, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current EV-to-EBITDA of 3.81 is 72.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TSH Biopharm. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current EV-to-EBITDA is 3.81, which is 69% below median its own 10-year median of 12.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$71.57, compared to a current price of NT$50.30 — trading 29.7% below its estimated fair value. The current EV-to-EBITDA is 3.81, which is 69% below median its 10-year median of 12.17 and 72.3% below the Drug Manufacturers industry median of 13.75. TSH Biopharm's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current EV-to-EBITDA is 3.81 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.30 is trading 29.7% below its estimated GF Value™ of NT$71.57.
GuruFocus considers TSH Biopharm to be Significantly Undervalued.
Key valuation signals for ROCO:8432:
EV-to-EBITDA: 3.81 (69% below median its 10-year median of 12.17)
GF Value™: NT$71.57 vs. price of NT$50.30 (29.7% below fair value)
Industry Position: 72.3% below the Drug Manufacturers median (#62 of 726)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
88GF Score
Get the complete analysis for ROCO:8432
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
